ADDED
We may in the future need to raise additional funding, which may not be available on acceptable terms to us, or at all.
Risks Inherent in Drug Development and Commercialization Preclinical and clinical development are both highly speculative and carry a high failure risk.
Our competitors may develop treatments for our product candidates target indications, which could limit our product candidates commercial opportunity and profitability, if approved.
We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
We have previously failed to satisfy certain continued listing rules of The Nasdaq Stock Market LLC ( Nasdaq ), and if we again are unable to meet the continued listing requirements and/or regain compliance with such rules, our Common Stock may be subject to delisting from The Nasdaq Capital Market.
The delisting of our Securities from Nasdaq may decrease the market liquidity and market price of our Common Stock.
( Mustang, we, us, our or the Company ) is a clinical-stage biopharmaceutical company focused on translating today s medical breakthroughs into potential cures for difficult-to-treat cancers.
Our pipeline is currently focused on novel therapies for solid tumors.
Development Pipeline Our pipeline is being developed under exclusive licenses from two world class research institutions.
Our strategy is to license these technologies, support preclinical and clinical research activities by our partners and develop these product candidates through to potential approval, We are developing a CAR T therapy for solid tumors in partnership with COH targeting IL13R 2 (MB-101).
REMOVED
There is substantial doubt regarding our ability to continue as a going concern.
We will need to raise additional financing in upcoming periods, which may not be available on acceptable terms to us, or at all.
Our strategic pivot and focus on our lead product candidates, MB-109 and MB-106, and our disposal of non-core assets, including our facility, may not result in the cost savings we anticipate and could result in total costs and expenses that are greater than expected.
Risks Inherent in Drug Development and Commercialization Preclinical development is highly speculative and carries a high failure risk.
Our competitors may develop treatments for our products target indications, which could limit our product candidates commercial opportunity and profitability.
Risks Relating to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries We operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations.
( Mustang, we, us, our or the Company ) is a clinical-stage biopharmaceutical company focused on translating today s medical breakthroughs into potential cures for difficult-to-treat cancers and autoimmune diseases.
Our pipeline is currently focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors.
CAR T Therapies Our pipeline of CAR T therapies is being developed under exclusive licenses from several world class research institutions.
Our strategy is to license these technologies, support preclinical and clinical research activities by our partners and transfer the underlying technology to our or our contract manufacturer s cell processing facility in order to conduct our own clinical trials.